| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Quoin Pharmaceuticals Ltd. (“we,” “us,” or the “Company”) held a Special General Meeting of Shareholders (the “Special Meeting”) on November 12, 2026. During the Special Meeting, shareholders were asked to consider and vote upon two prop... |
| 06 Nov 2026 |
8-K: Results of Operations and Financial Condition
– Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome; Primary and Key Secondary Endpoints Achieved Statistical Significance Versus Pre-Specified Alpha-Adjusted Target |
| 04 Nov 2026 |
8-K: Entry into a Material Definitive Agreement
Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: |
| 20 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy |
| 14 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome |
| 22 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy |
| 10 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome |
| 28 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of August 27, 2026, by and among Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), and each of the entities listed on Exhibit A att... |
| 20 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders +1 more
Quoin Pharmaceuticals Ltd. (“we,” “us,” or the “Company”) held its 2026 Annual General Meeting of Shareholders (the “Annual Meeting”) on August 20, 2026. At the Annual Meeting, shareholders approved changes to the matching contributions ... |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition
– Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome |
| 23 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome |
| 04 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
-Designation provides regulatory and development incentives in Japan, including up to 10 years of market exclusivity upon approval- |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
– Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome |
| 26 Mar 2026 |
8-K: Results of Operations and Financial Condition
– Closes Private Placement Financing of Up to $104.5 Million |
| 11 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
— Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need — |
| 20 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome |
| 17 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
This Grant Notification Letter (this “Agreement”) evidences a non-qualified stock option granted by Quoin Pharmaceuticals Ltd. (the “Company”) to the individual named above (the “Optionee”), pursuant to and subject to the terms of the Qu... |
| 12 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
- Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D |
| 21 Oct 2025 |
8-K: Regulation FD Disclosure; Other Events
Upon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the US |
Loading...